vs
Side-by-side financial comparison of AvalonBay Communities (AVB) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
AvalonBay Communities is the larger business by last-quarter revenue ($767.9M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). AvalonBay Communities runs the higher net margin — 9040.6% vs 19.1%, a 9021.5% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 3.7%). AvalonBay Communities produced more free cash flow last quarter ($1.4B vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 3.8%).
AvalonBay Communities, Inc. is a publicly traded real estate investment trust that invests in apartments.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
AVB vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $767.9M | $708.5M |
| Net Profit | $166.0M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 64.2% | 21.6% |
| Net Margin | 9040.6% | 19.1% |
| Revenue YoY | 3.7% | 32.0% |
| Net Profit YoY | -41.2% | 15.5% |
| EPS (diluted) | $1.18 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $767.9M | $708.5M | ||
| Q3 25 | $766.8M | $659.9M | ||
| Q2 25 | $760.2M | $603.3M | ||
| Q1 25 | $745.9M | $558.6M | ||
| Q4 24 | $740.5M | $536.6M | ||
| Q3 24 | $734.3M | $533.3M | ||
| Q2 24 | $726.0M | $528.1M | ||
| Q1 24 | $712.9M | $511.0M |
| Q4 25 | $166.0M | $135.1M | ||
| Q3 25 | $381.3M | $111.1M | ||
| Q2 25 | $268.7M | $90.3M | ||
| Q1 25 | $236.6M | $114.6M | ||
| Q4 24 | $282.1M | $117.0M | ||
| Q3 24 | $372.5M | $96.4M | ||
| Q2 24 | $253.9M | $88.4M | ||
| Q1 24 | $173.4M | $102.6M |
| Q4 25 | 64.2% | 21.6% | ||
| Q3 25 | 65.7% | 21.5% | ||
| Q2 25 | 67.6% | 20.9% | ||
| Q1 25 | 68.5% | 20.3% | ||
| Q4 24 | 63.1% | 23.4% | ||
| Q3 24 | 65.4% | 21.1% | ||
| Q2 24 | 66.6% | 19.9% | ||
| Q1 24 | 67.2% | 20.4% |
| Q4 25 | 9040.6% | 19.1% | ||
| Q3 25 | 49.7% | 16.8% | ||
| Q2 25 | 35.3% | 15.0% | ||
| Q1 25 | 31.7% | 20.5% | ||
| Q4 24 | 38.1% | 21.8% | ||
| Q3 24 | 50.7% | 18.1% | ||
| Q2 24 | 35.0% | 16.7% | ||
| Q1 24 | 24.3% | 20.1% |
| Q4 25 | $1.18 | $4.65 | ||
| Q3 25 | $2.68 | $3.86 | ||
| Q2 25 | $1.88 | $3.10 | ||
| Q1 25 | $1.66 | $3.67 | ||
| Q4 24 | $1.99 | $3.67 | ||
| Q3 24 | $2.61 | $3.01 | ||
| Q2 24 | $1.78 | $2.75 | ||
| Q1 24 | $1.22 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $187.2M | $497.0M |
| Total DebtLower is stronger | $9.3B | — |
| Stockholders' EquityBook value | $11.6B | $459.1M |
| Total Assets | $22.2B | $2.0B |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $187.2M | $497.0M | ||
| Q3 25 | $123.3M | $285.4M | ||
| Q2 25 | $102.8M | $46.3M | ||
| Q1 25 | $53.3M | $441.4M | ||
| Q4 24 | $108.6M | $669.4M | ||
| Q3 24 | $552.4M | $656.9M | ||
| Q2 24 | $545.8M | $510.9M | ||
| Q1 24 | $287.9M | $407.0M |
| Q4 25 | $9.3B | — | ||
| Q3 25 | $8.7B | — | ||
| Q2 25 | $8.7B | — | ||
| Q1 25 | $8.3B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $8.4B | — | ||
| Q2 24 | $8.4B | — | ||
| Q1 24 | $8.0B | — |
| Q4 25 | $11.6B | $459.1M | ||
| Q3 25 | $11.9B | $293.6M | ||
| Q2 25 | $11.9B | $172.4M | ||
| Q1 25 | $11.9B | $593.6M | ||
| Q4 24 | $11.9B | $825.5M | ||
| Q3 24 | $11.9B | $881.4M | ||
| Q2 24 | $11.7B | $763.6M | ||
| Q1 24 | $11.7B | $671.5M |
| Q4 25 | $22.2B | $2.0B | ||
| Q3 25 | $21.9B | $1.8B | ||
| Q2 25 | $21.8B | $1.6B | ||
| Q1 25 | $21.2B | $1.9B | ||
| Q4 24 | $21.0B | $2.1B | ||
| Q3 24 | $21.3B | $2.1B | ||
| Q2 24 | $21.0B | $1.9B | ||
| Q1 24 | $20.6B | $1.8B |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7B | $192.7M |
| Free Cash FlowOCF − Capex | $1.4B | $188.1M |
| FCF MarginFCF / Revenue | 183.5% | 26.6% |
| Capex IntensityCapex / Revenue | 34.1% | 0.6% |
| Cash ConversionOCF / Net Profit | 10.07× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $2.5B | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $192.7M | ||
| Q3 25 | $477.0M | $246.2M | ||
| Q2 25 | $377.8M | $148.5M | ||
| Q1 25 | $415.9M | $125.8M | ||
| Q4 24 | $1.6B | $190.7M | ||
| Q3 24 | $486.2M | $149.1M | ||
| Q2 24 | $380.0M | $116.4M | ||
| Q1 24 | $412.9M | $152.7M |
| Q4 25 | $1.4B | $188.1M | ||
| Q3 25 | $402.2M | $235.5M | ||
| Q2 25 | $317.1M | $142.4M | ||
| Q1 25 | $367.5M | $115.8M | ||
| Q4 24 | $1.4B | $183.0M | ||
| Q3 24 | $434.2M | $138.5M | ||
| Q2 24 | $333.0M | $103.5M | ||
| Q1 24 | $375.4M | $147.2M |
| Q4 25 | 183.5% | 26.6% | ||
| Q3 25 | 52.5% | 35.7% | ||
| Q2 25 | 41.7% | 23.6% | ||
| Q1 25 | 49.3% | 20.7% | ||
| Q4 24 | 191.0% | 34.1% | ||
| Q3 24 | 59.1% | 26.0% | ||
| Q2 24 | 45.9% | 19.6% | ||
| Q1 24 | 52.7% | 28.8% |
| Q4 25 | 34.1% | 0.6% | ||
| Q3 25 | 9.8% | 1.6% | ||
| Q2 25 | 8.0% | 1.0% | ||
| Q1 25 | 6.5% | 1.8% | ||
| Q4 24 | 26.1% | 1.4% | ||
| Q3 24 | 7.1% | 2.0% | ||
| Q2 24 | 6.5% | 2.4% | ||
| Q1 24 | 5.3% | 1.1% |
| Q4 25 | 10.07× | 1.43× | ||
| Q3 25 | 1.25× | 2.22× | ||
| Q2 25 | 1.41× | 1.65× | ||
| Q1 25 | 1.76× | 1.10× | ||
| Q4 24 | 5.70× | 1.63× | ||
| Q3 24 | 1.31× | 1.55× | ||
| Q2 24 | 1.50× | 1.32× | ||
| Q1 24 | 2.38× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVB
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
